Docoh
Loading...

PRPO Precipio

Filed: 20 Jan 04, 7:00pm
================================================================================

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):
                                January 20, 2004

                               TRANSGENOMIC, INC.
             (Exact name of registrant as specified in its charter)

              Delaware                                     000-30975
        (State of Formation)                       (Commission File Number)

                                    911789357
                      (IRS Employer Identification Number)

            12325 Emmet Street
                 Omaha, NE                                   68164
  (Address of principal executive offices)                 (Zip Code)

                                 (402) 452-5400
              (Registrants' telephone number, including area code)

                                 Not applicable
          (Former name or former address, if changed since last report)

================================================================================



Item 5. Other Events and Regulation FD Disclosure.

      On January 20, 2004, the Company issued a press release announcing it has
entered into an agreement with SpectruMedix LLC to distribute its RevealTM
Genetic Analysis Systems in Europe. A copy of the press release is filed
herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 7. Financial Statements and Exhibits.

(c) Exhibits

99.1  Press Release, dated January 20, 2004, announcing that the Company has
      entered into an agreement with SpectruMedix LLC to distribute its RevealTM
      Genetic Analysis Systems in Europe.


                                       2



                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                   TRANSGENOMIC, INC.

                                   By /s/ Michael J. Draper
                                   ---------------------------------------------
                                   Michael J. Draper, Chief Financial Officer

January 20, 2004


                                       3